{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:31Z","timestamp":1792190611340,"version":"4.4.0"},"reference-count":38,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01HL160716-01"],"award-info":[{"award-number":["1R01HL160716-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5K08HLO145108-03"],"award-info":[{"award-number":["5K08HLO145108-03"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 CA-194042"],"award-info":[{"award-number":["RO1 CA-194042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,11,15]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The response of solid tumors such as papillary thyroid cancer (PTC) to immune checkpoint inhibitors (ICIs) is highly variable. The biological basis of this variability remains unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To test the hypothesis that preconditioning of the immune system modulates the therapeutic effect of ICIs, we used a murine model where PTC and iodine exacerbated thyroiditis (IET) can be induced in a temporally predictable fashion. A total of 122 mice were divided into 3 experimental groups. In the first one, named concomitant IET and PTC (No.=40), IET, and PTC were induced at the same time; in the second one, named pre-existing IET (No.=44), IET was induced prior to the induction of PTC; in the third one, named no IET (No.=38), only PTC was induced. Following disease induction, mice of each group were treated with anti-PD-1 antibody, anti-lymphocyte activation gene 3 antibody (anti-Lag3), anti-T-cell immunoglobulin and mucin domain 3 antibody (anti-Tim3), or IgG control. Ten weeks after the initial ICI injection, mice were sacrificed to collect the thyroid gland for histological analysis, to quantify the incidence and burden of PTC, and to perform high-throughput single-cell RNA sequencing of infiltrating CD45<jats:sup>+<\/jats:sup> cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the concomitant IET and PTC group, ICI treatment reduced PTC incidence (p=0.002 comparing treatment with any ICI vs control), while it had no effect in the pre-existing IET and no IET groups. Single-cell sequencing of thyroidal CD45<jats:sup>+<\/jats:sup> cells showed that the different ICIs tested had both specific and shared effects on all the components of the thyroidal immune cell infiltrate. The shared effect of the tested ICIs was dependent on the presence of pre-existing versus concomitant IET. In the context of concomitant IET, ICI treatment resulted in the modulation of a greater number of pathways related to both innate and adaptive immunity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Response to ICIs depends on the status of the immune system of the treated individual. Modulation of the immune system should be explored as a tool to improve response to ICIs in patients with PTC or other forms of cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005538","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T09:52:29Z","timestamp":1671097949000},"page":"e005538","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2566-7971","authenticated-orcid":false,"given":"Fabiana","family":"Pani","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"GRC No. 16, GRC Tumeurs Thyro\u00efdiennes, Thyroid and Endocrine Tumors Department; Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0674-2956","authenticated-orcid":false,"given":"Yoshinori","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Division of Immunology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8196-5415","authenticated-orcid":false,"given":"Sylvie T","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C","family":"Bermea","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solmaz","family":"Roshanmehr","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rulin","family":"Wang","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Yegnasubramanian","sequence":"additional","affiliation":[{"name":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Caturegli","sequence":"additional","affiliation":[{"name":"Division of Immunology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-978X","authenticated-orcid":false,"given":"Luigi","family":"Adamo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"2025100303385812000_10.12.e005538.1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83871"},{"key":"2025100303385812000_10.12.e005538.2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41574-020-0398-9","article-title":"Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies","volume":"16","author":"French","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2025100303385812000_10.12.e005538.3","doi-asserted-by":"crossref","first-page":"100095","DOI":"10.1016\/j.esmoop.2021.100095","article-title":"Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it","volume":"6","author":"Trestini","year":"2021","journal-title":"ESMO Open"},{"key":"2025100303385812000_10.12.e005538.4","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100303385812000_10.12.e005538.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706"},{"key":"2025100303385812000_10.12.e005538.6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00262-019-02318-8","article-title":"Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition","volume":"68","author":"Chat","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100303385812000_10.12.e005538.7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0698-6"},{"key":"2025100303385812000_10.12.e005538.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-022-01004-8","article-title":"Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients","volume":"22","author":"Baek","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"2025100303385812000_10.12.e005538.9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2025100303385812000_10.12.e005538.10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8"},{"key":"2025100303385812000_10.12.e005538.11","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab144","article-title":"Pre-existing thyroiditis ameliorates papillary thyroid cancer: insights from a new mouse model","volume":"162","author":"Pani","year":"2021","journal-title":"Endocrinology"},{"key":"2025100303385812000_10.12.e005538.12","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-Infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100303385812000_10.12.e005538.13","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"2025100303385812000_10.12.e005538.14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1053\/j.seminoncol.2019.08.005","article-title":"Significance of TIM3 expression in cancer: from biology to the clinic","volume":"46","author":"Solinas","year":"2019","journal-title":"Semin Oncol"},{"key":"2025100303385812000_10.12.e005538.15","doi-asserted-by":"publisher","DOI":"10.1177\/43.3.7868864"},{"key":"2025100303385812000_10.12.e005538.16","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn923"},{"key":"2025100303385812000_10.12.e005538.17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40618-017-0778-8","article-title":"Thyroid dysfunctions secondary to cancer immunotherapy","volume":"41","author":"Chalan","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"2025100303385812000_10.12.e005538.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640"},{"key":"2025100303385812000_10.12.e005538.19","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41416-020-0736-7","article-title":"Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study","volume":"122","author":"Okada","year":"2020","journal-title":"Br J Cancer"},{"key":"2025100303385812000_10.12.e005538.20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"key":"2025100303385812000_10.12.e005538.21","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3803\/EnM.2021.1007","article-title":"Clinical characteristics, management, and potential biomarkers of endocrine dysfunction induced by immune checkpoint inhibitors","volume":"36","author":"Iwama","year":"2021","journal-title":"Endocrinol Metab"},{"key":"2025100303385812000_10.12.e005538.22","doi-asserted-by":"crossref","first-page":"101660","DOI":"10.1016\/j.beem.2022.101660","article-title":"Immune checkpoint inhibitor-related thyroid dysfunction","volume":"36","author":"Iwama","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2025100303385812000_10.12.e005538.23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"2025100303385812000_10.12.e005538.24","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4049\/jimmunol.155.4.1776","article-title":"Activated T cells can induce high levels of CTLA-4 expression on B cells","volume":"155","author":"Kuiper","year":"1995","journal-title":"J Immunol"},{"key":"2025100303385812000_10.12.e005538.25","doi-asserted-by":"crossref","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid immune-related adverse events following immune checkpoint inhibitor treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100303385812000_10.12.e005538.26","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"2025100303385812000_10.12.e005538.27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.pathol.2019.10.010","article-title":"Unique and distinctive histological features of immunotherapy-related thyroiditis","volume":"52","author":"Zaborowski","year":"2020","journal-title":"Pathology"},{"key":"2025100303385812000_10.12.e005538.28","doi-asserted-by":"crossref","first-page":"e1843","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events","volume":"107","author":"Muir","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025100303385812000_10.12.e005538.29","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"2025100303385812000_10.12.e005538.30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184413","article-title":"Immune and inflammatory cells in thyroid cancer microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025100303385812000_10.12.e005538.31","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0316"},{"key":"2025100303385812000_10.12.e005538.32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2912"},{"key":"2025100303385812000_10.12.e005538.33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000371741","article-title":"Iodine, thyroid autoimmunity and cancer","volume":"4","author":"Fiore","year":"2015","journal-title":"Eur Thyroid J"},{"key":"2025100303385812000_10.12.e005538.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1568-9972(01)00016-7"},{"key":"2025100303385812000_10.12.e005538.35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12026-021-09192-6","article-title":"Iodoprophylaxis and thyroid autoimmunity: an update","volume":"69","author":"Teti","year":"2021","journal-title":"Immunol Res"},{"key":"2025100303385812000_10.12.e005538.36","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0662-5"},{"key":"2025100303385812000_10.12.e005538.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1509"},{"key":"2025100303385812000_10.12.e005538.38","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103679","article-title":"Immunotherapy for head and neck cancer: present and future","volume":"174","author":"Fasano","year":"2022","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:39:05Z","timestamp":1759487945000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,15]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1136\/jitc-2022-005538"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005538","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}